Format

Send to

Choose Destination
See comment in PubMed Commons below
J Appl Microbiol. 2013 Aug;115(2):319-33. doi: 10.1111/jam.12174. Epub 2013 Mar 13.

Immunotherapy of allergic diseases using probiotics or recombinant probiotics.

Author information

1
Laboratório de Genética Celular e Molecular, Instituto de Ciências Biológicas, Universidade Federal de Minas Gerais (ICB/UFMG), Belo Horizonte, MG, Brazil.

Abstract

Allergic diseases affect up to 30% of the western population, and their prevalence is increasing. Probiotics are able to modulate the mucosal immune response, and clinical trials demonstrated that specific strains, especially lactic acid bacteria (LAB) ones, reduce allergic symptoms. Moreover, the use of recombinant probiotics has been evaluated as possible strategies for the immunotherapy of allergic diseases. The production and delivery of allergens by recombinant LAB in concert with their ability to induce a Th1-type immune response have been shown to be a promising mucosal vaccination strategy in mouse model. The aim of this article is to review the applications of probiotics in allergy immunotherapy with a special focus on recombinant LAB delivering proteins or DNA.

KEYWORDS:

allergic diseases; allergy treatment; immunotherapy; lactic acid bacteria; recombinant probiotics; β-lactoglobulin

PMID:
23437848
DOI:
10.1111/jam.12174
[Indexed for MEDLINE]
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Wiley
    Loading ...
    Support Center